Related Experiment Video
Updated: Jun 20, 2026
Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease
Published on: May 13, 2010
"Doctor, if it were you, which would you choose?": Navigating personal preference questions in anti-amyloid
1UT Tyler Neurology Department The University of Texas Tyler Dementia Center Tyler Texas USA.
Abstract:
The approval of lecanemab and donanemab represents a watershed moment in Alzheimer Disease (AD) treatment, yet clinicians face a novel challenge: guiding patients through treatment selection when head-to-head comparative data are absent. When confronted with the question "What would you do if you were me?", clinical providers must balance evidence-based medicine with the therapeutic alliance. This perspective examines the ethical, practical, and relational dimensions of responding to personal preference queries in the context of anti-amyloid immunotherapy selection, offering a framework for authentic engagement that honors both professional boundaries and patient-centered care.
Insights
New Alzheimer Disease (AD) treatments like lecanemab and donanemab offer hope, but lack direct comparison data. Clinicians must navigate patient preferences ethically while maintaining the therapeutic alliance for optimal care.
Area of Science:
- Neurology
- Medical Ethics
Background:
- Lecanemab and donanemab represent significant advancements in Alzheimer Disease (AD) treatment.
- The absence of head-to-head comparative data for these anti-amyloid immunotherapies presents a clinical challenge.
Purpose of the Study:
- To examine the ethical, practical, and relational aspects of responding to patient preference queries regarding AD immunotherapy selection.
- To offer a framework for clinicians to engage patients authentically, balancing professional responsibilities with patient-centered care.
Main Methods:
- This perspective piece analyzes the complexities of treatment selection in the context of novel AD therapies.
- It explores the intersection of evidence-based medicine, therapeutic alliance, and patient autonomy.
Main Results:
- Clinicians face the challenge of guiding treatment choices without direct comparative efficacy data.
- Responding to "What would you do if you were me?" requires careful consideration of multiple dimensions.
Conclusions:
- A framework is proposed for authentic engagement that respects professional boundaries and prioritizes patient-centered care in AD immunotherapy decisions.
- Ethical and relational strategies are crucial for navigating treatment selection in the evolving landscape of Alzheimer Disease therapeutics.
